Detail akcie Adagio Med Rg online

Business Summary: Adagio Medical Holdings, Inc. is a commercial stage medical device company. It is focused on developing proprietary Ultra-Low Temperature Cryoablation technology that creates contiguous, transmural lesions to treat cardiac arrhythmias, with an emphasis on ventricular tachycardia. It is developing and placing on the European Union (EU) market ablation technologies for the treatment of cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. Its product portfolio consists of three product families: iCLAS atrial ULTC catheter and accessories, vCLAS ventricular ULTC catheter, and Cryopulse atrial PFCA catheter and accessories. All of these catheters share the same ULTC cryoablation console. The iCLAS system is CE-marked with the indication for treatment of paroxysmal atrial fibrillation, persistent atrial fibrillation and atrial flutter. The vCLAS ventricular catheter has been specifically designed for the treatment of ventricular arrhythmia.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Adagio Medical Holdings Inc revenues decreased from $465K to $0K. Net loss increased 23% to $21.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Convertible notes fair value adjustment decrease from $5.3M (income) to $1.9M (expense).